Juno Therapeutics, Inc.
SEATTLE, WA · Founded 2013 · CIK 0001594864 · Biotech · Acquired
CAR-T cell immunotherapies for cancer treatment
juno.ai →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $1.0B
- 5 Form D · Oct 2017
- 108 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201320142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,667,672 | |
| Private capital raised | Form D · SEC | $28,423,971 | |
| Private capital raised | Form D · SEC | $85,499,985 | |
| Private capital raised | Form D · SEC | $849,803,496 | |
| Private capital raised | Form D · SEC | $31,091,407 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1528 | StabiLux Biosciences, Inc | — | $554K |
| 1529 | PGI HOLDING CORPORATION | — | — |
| 1530 | EUNOIA BIO TECH, LLC | — | — |
| 1531 | Juno Therapeutics, Inc. | — | $1.0B |
| 1532 | SYNAPTOGENIX, INC. | — | — |
| 1533 | Akeso | — | — |
| 1534 | Ctrl Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sunil AgarwalExecutive Officer
- Robert AzelbyExecutive Officer
- Hal BarronDirector
- Hans BishopDirector · Executive Officer · Promoter
- Bernard CassidyExecutive Officer
- Larry CoreyDirector
- Thomas DanielDirector
- Anthony EvninDirector
- Jay FlatleyDirector
- Mark FrohlichExecutive Officer · Promoter
- Steven HarrExecutive Officer
- Richard KlausnerDirector · Promoter
- Rick KlausnerDirector · Promoter
- Hyam LevitskyExecutive Officer
- Robert NelsenDirector · Promoter
- Howard PienDirector
- Marc Tessier-LavigneDirector
- Rupert VesseyDirector
- Mary WilderotterDirector
Patents
- Stabilization Of Polyethyleneimine-deoxyribonucleic Acid Complex Size And Activitygranted
- Methods For Culturing Cells And Kits And Apparatus For Sameapplication
- Method Of Assessing Activity Of Recombinant Antigen Receptorsgranted
- Process For Producing Donor-batched Cells Expressing A Recombinant Receptorgranted
- Methods, Compositions And Components For CRISPR-CAS9 Editing Of TGFBR2 In T Cells For Immunotherapygranted
- Methods For Treatment Using Adoptive Cell Therapyapplication
- Methods For Isolating, Culturing, And Genetically Engineering Immune Cell Populations For Adoptive Therapyapplication
- Methods For Isolating, Culturing, And Genetically Engineering Immune Cell Populations For Adoptive Therapyapplication
- Anti-idiotypic Antibodies To Bcma-targeted Binding Domains And Related Compositions And Methodsgranted
- Methods For Isolating, Culturing, And Genetically Engineering Immune Cell Populations For Adoptive Therapyapplication
- Threshold Gating For Flow Cytometry Methodsapplication
- Antibodies And Chimeric Antigen Receptors Specific For CD19granted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.